The CDKN2A locus on human chromosome 9p21 encodes two proteins named p16INK4a and p14ARF, known to function as tumour suppressors via the retinoblastoma (Rb) or the p53 pathway. The p53 tumour suppressor gene is the most commonly mutated gene in human and mouse cancers. Disruption of the p53 and Rb pathways is a fundamental trend of most human cancer cells. Recent studies have shown that the CDKN2A gene plays an active role in the p53 and Rb tumour suppressor pathways. Genetic abnormalities in CDKN2A have been well documented in human melanoma, but their involvement in nonmelanoma skin cancer (NMSC) is less clear.
Pacifico, A., Goldberg, L., Peris, K., Chimenti, S., Leone, G., Ananthaswamy, H., Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers, <<BRITISH JOURNAL OF DERMATOLOGY>>, 2008; 158 (2): 291-297. [doi:10.1111/j.1365-2133.2007.08360.x] [http://hdl.handle.net/10807/57532]
Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers
Peris, Ketty;
2008
Abstract
The CDKN2A locus on human chromosome 9p21 encodes two proteins named p16INK4a and p14ARF, known to function as tumour suppressors via the retinoblastoma (Rb) or the p53 pathway. The p53 tumour suppressor gene is the most commonly mutated gene in human and mouse cancers. Disruption of the p53 and Rb pathways is a fundamental trend of most human cancer cells. Recent studies have shown that the CDKN2A gene plays an active role in the p53 and Rb tumour suppressor pathways. Genetic abnormalities in CDKN2A have been well documented in human melanoma, but their involvement in nonmelanoma skin cancer (NMSC) is less clear.
| Campo DC | Valore | Lingua |
|---|---|---|
| dc.authority.academicField2000 | Settore MED/35 - MALATTIE CUTANEE E VENEREE | it |
| dc.authority.ancejournal | BRITISH JOURNAL OF DERMATOLOGY | en |
| dc.authority.erc2011 | Cancer and its biological basis | it |
| dc.authority.people | Pacifico, A | - |
| dc.authority.people | Goldberg, Lh | - |
| dc.authority.people | Peris, Ketty | it |
| dc.authority.people | Chimenti, S | - |
| dc.authority.people | Leone, G | - |
| dc.authority.people | Ananthaswamy, Hn | - |
| dc.cilea.flagannuariosi | 15200940 | - |
| dc.cilea.flagppdsi | 15200940 | - |
| dc.date.accessioned | 2014-05-05T18:53:04Z | - |
| dc.date.available | 2014-05-05T18:53:04Z | - |
| dc.date.issued | 2008 | - |
| dc.description.abstracteng | The CDKN2A locus on human chromosome 9p21 encodes two proteins named p16INK4a and p14ARF, known to function as tumour suppressors via the retinoblastoma (Rb) or the p53 pathway. The p53 tumour suppressor gene is the most commonly mutated gene in human and mouse cancers. Disruption of the p53 and Rb pathways is a fundamental trend of most human cancer cells. Recent studies have shown that the CDKN2A gene plays an active role in the p53 and Rb tumour suppressor pathways. Genetic abnormalities in CDKN2A have been well documented in human melanoma, but their involvement in nonmelanoma skin cancer (NMSC) is less clear. | - |
| dc.description.allpeople | Pacifico, A; Goldberg, Lh; Peris, Ketty; Chimenti, S; Leone, G; Ananthaswamy, Hn | - |
| dc.description.allpeopleoriginal | Pacifico, A; Goldberg, Lh; Peris, Ketty; Chimenti, S; Leone, G; Ananthaswamy, Hn | it |
| dc.description.fulltext | none | en |
| dc.description.fulltextoriginal | none | en |
| dc.description.languageisokeywords | eng | it |
| dc.description.numberofauthors | 6 | - |
| dc.identifier.citation | Pacifico, A., Goldberg, L., Peris, K., Chimenti, S., Leone, G., Ananthaswamy, H., Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers, <<BRITISH JOURNAL OF DERMATOLOGY>>, 2008; 158 (2): 291-297. [doi:10.1111/j.1365-2133.2007.08360.x] [http://hdl.handle.net/10807/57532] | it |
| dc.identifier.doi | 10.1111/j.1365-2133.2007.08360.x | it |
| dc.identifier.pmid | 18070208 | - |
| dc.identifier.uri | http://hdl.handle.net/10807/57532 | - |
| dc.language.iso | eng | it |
| dc.publisher.name | Blackwell | it |
| dc.relation.firstpage | 291 | it |
| dc.relation.issue | 2 | it |
| dc.relation.issueyear | 2008 | it |
| dc.relation.lastpage | 297 | it |
| dc.relation.numberofpages | 7 | it |
| dc.relation.volume | 158 | it |
| dc.source.pubmed | 18070208 | en |
| dc.subject.keywords | Genes, p16 | it |
| dc.subject.keywords | Mutation | it |
| dc.subject.keywords | Adult | it |
| dc.subject.keywords | Aged | it |
| dc.subject.keywords | Aged, 80 and over | it |
| dc.subject.keywords | Carcinoma, Basal Cell | it |
| dc.subject.keywords | Carcinoma, Squamous Cell | it |
| dc.subject.keywords | Female | it |
| dc.subject.keywords | Humans | it |
| dc.subject.keywords | Keratosis | it |
| dc.subject.keywords | Male | it |
| dc.subject.keywords | Middle Aged | it |
| dc.subject.keywords | Skin Neoplasms | it |
| dc.subject.keywords | Tumor Suppressor Protein p14ARF | it |
| dc.title | Loss of CDKN2A and p14ARF expression occurs frequently in human nonmelanoma skin cancers | it |
| dc.type | art_per_29 | it |
| dc.type.full | 03. Contributo in rivista::Articolo in rivista, Nota a sentenza | it |
| dc.type.genius | Pubblicazione su rivista con Impact Factor | - |
| dc.type.miur | 262 | en |
| dc.type.miurarticle | Articolo in rivista | it |
| dc.type.research | AREA06 - SCIENZE MEDICHE | - |
| iris.unpaywall.doi | 10.1111/j.1365-2133.2007.08360.x | * |
| iris.unpaywall.isoa | false | * |
| iris.unpaywall.journalisindoaj | false | * |
| iris.unpaywall.metadataCallLastModified | 15/06/2024 02:33:51 | - |
| iris.unpaywall.metadataCallLastModifiedMillisecond | 1718411631522 | - |
| iris.unpaywall.oastatus | closed | * |
| Appare nelle tipologie: | Articolo in rivista, Nota a sentenza | |
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
